Foundation for Neglected Disease Research (FNDR) and DevsHealth have joined forces in a collaborative effort to discover and develop cost-effective drugs for mosquito-borne infections using AI/ML technology. The project aims to create broad-spectrum antiviral agents to combat flaviviruses such as dengue, Zika, West Nile virus, and Japanese encephalitis, which collectively cause over 400 million human infections annually. While most cases result in mild, self-limiting febrile episodes, some infections can lead to severe and life-threatening conditions like haemorrhagic fever and encephalitis, particularly impacting low- and middle-income countries. The escalating cases of flavivirus infections due to climate change underscore the urgency of this collaboration.
This partnership between FNDR and DevsHealth marks a significant step towards revolutionizing the treatment of flavivirus infections, for which no specific drugs currently exist. By leveraging AI/ML technology and real-world data, DevsHealth, a DeepTech company specializing in anti-infectious drug development, will collaborate with FNDR, an expert in drug discovery for infectious and neglected diseases. DevsHealth will primarily focus on in silico studies and chemistry efforts, while FNDR will oversee in vitro and in vivo experiments to expedite the discovery of new broad-spectrum antiviral agents for flaviviruses. The ultimate goal is to make these treatments both effective and accessible to patients in need, especially in regions heavily impacted by these diseases.
FNDR, as a not-for-profit biotech R&D organization, has a track record of developing novel therapeutics for a range of diseases with high socio-economic implications, including tuberculosis, malaria, and COVID-19. With state-of-the-art laboratories in Bengaluru, India, FNDR’s research efforts align with the One Health approach, addressing global health challenges such as antimicrobial resistance and pandemic preparedness. On the other hand, DevsHealth, founded in 2021, specializes in applying AI, real-world data analysis, and molecular modeling to accelerate the development of anti-infectious treatments. Their mission to leverage technology for healthcare improvement resonates with FNDR’s commitment to combining AI/ML technologies with in vitro and in vivo capabilities for drug discovery.
The collaboration between FNDR and DevsHealth signifies a strategic alignment of expertise and resources to tackle the pressing issue of mosquito-borne infections. By combining FNDR’s research capabilities and DevsHealth’s technological platform, the consortium aims to deliver breakthrough solutions for flavivirus infections. This partnership not only underscores the power of collaboration in the biotech industry but also highlights the potential of AI/ML technologies to drive innovation in drug discovery and development. With the shared goal of accelerating the availability of affordable antiviral drugs for neglected diseases, this collaboration represents a promising step towards addressing global health challenges.
Key Takeaways:
– FNDR and DevsHealth’s collaboration targets the development of affordable, broad-spectrum antiviral drugs for flaviviruses, addressing the significant burden of mosquito-borne infections.
– Leveraging AI/ML technology and expertise in drug discovery, the partnership aims to accelerate the discovery and development of novel treatments for flavivirus infections.
– FNDR’s track record in neglected disease research, combined with DevsHealth’s AI-driven approach, showcases the potential of interdisciplinary collaborations in advancing healthcare solutions.
– The strategic partnership between FNDR and DevsHealth highlights the importance of leveraging cutting-edge technologies and research capabilities to address global health challenges.
Tags: clinical trials, biotech, pandemic preparedness
Read more on aninews.in